FAsenra Safety Trial in India - FAST

Study identifier:D3250C00093

ClinicalTrials.gov identifier:NCT05384938

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Postmarketing, Phase 4, Multicentre, Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India.

Medical condition

In Adult Patients of Severe Asthma with Eosinophilic Phenotype in India

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

139

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 19 Nov 2021
Primary Completion Date: 01 Jul 2023
Study Completion Date: 01 Jul 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Not Applicable

Inclusion and exclusion criteria